Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Targeted therapies

Tailored treatment for ovarian cancer: are we there yet?

Nature Reviews Clinical Oncology volume 7, pages 80–82 (2010)Cite this article

Subjects

First-line platinum and taxane chemotherapy improves the prognosis of patients with epithelial ovarian cancer (EOC), however, about 80% of patients relapse and long-term survival is poor. The development of drug resistance is the main cause of treatment failure; therefore, the identification of new compounds that interfere with tumor growth and survival is a priority.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Spannuth, W. A., Sood, A. K. & Coleman, R. L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 5, 194–204, (2008).

    Article  CAS  Google Scholar 

  2. Kaye, S. B. Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J. Clin. Oncol. 25, 5150–5152 (2007).

    Article  CAS  Google Scholar 

  3. Cannistra, S. A. et al. Phase II study of bevacizumab in patients with platinum persistent ovarian cancer or peritoneal serous cancer. J. Clin. Oncol. 25; 5180–5186 (2007).

    Article  CAS  Google Scholar 

  4. Burger, R. A., Sill, M. W., Monk, B. J., Greer, B. E. & Sorosky, J. I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J. Clin. Oncol. 25, 5165–5171 (2007).

    Article  CAS  Google Scholar 

  5. Zweifel, M. et al. Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum resistant ovarian cancer: final phase II trial results [abstract]. J. Clin. Oncol. 27 (Suppl.), a5502 (2009).

    Google Scholar 

  6. Watanabe, Y., Koi, M., Hemmi, H. A. Hoshai, H. & Noda, K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br. J. Cancer 85, 1064–1069 (2001).

    Article  CAS  Google Scholar 

  7. Fong, P. C. et al. Inhibition of Poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).

    Article  CAS  Google Scholar 

  8. Audeh, M. W. et al. Phase II trial of the oral PARP inhibitor olaparib (AZD 2281) in BRCA deficient advanced ovarian cancer. J. Clin. Oncol. 27 (Suppl.), a5500 (2009).

    Google Scholar 

  9. Turner, N., Tutt, A. & Ashworth, A. Hallmark of “BRCAness” in sporadic cancer. Nat. Rev. Cancer 4, 814–819 (2004).

    Article  CAS  Google Scholar 

  10. Kurman, R. J. & Shih, IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int. J. Gynecol. Pathol. 27, 151–160 (2008).

    PubMed  PubMed Central  Google Scholar 

  11. Hu, L., Hofmann, J., Lu, Y., Mills, G. B. & Jaffe, R. B. Inhibition of phosphatidylinositol 3 kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer Res. 62, 1087–1992 (2002).

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology Institute of Southern Switzerland (IOSI), Ospedale Regionale Bellinzona e Valli, 6500, Bellinzona, Switzerland

    Cristiana Sessa & Gianluca Del Conte

Authors
  1. Cristiana Sessa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gianluca Del Conte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cristiana Sessa.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sessa, C., Del Conte, G. Tailored treatment for ovarian cancer: are we there yet?. Nat Rev Clin Oncol 7, 80–82 (2010). https://doi.org/10.1038/nrclinonc.2009.233

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2009.233

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing